GlassScriptPhysician profile
Carrie Judy
NPI 1932195559
$2,883.14
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $757 · 2021: $548 · 2022: $424 · 2023: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $329.27 | 2019-2023 | Farxiga |
| Amgen INC. | $263.10 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.60 | 2019-2023 | Xifaxan |
| Pfizer INC. | $251.56 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.26 | 2019-2023 | Synjardy, Jardiance |
| Novo Nordisk INC | $197.69 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $151.05 | 2019-2021 | |
| Lilly USA, LLC | $143.60 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.75 | 2022 | |
| Merck Sharp & Dohme LLC | $95.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $93.39 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $85.91 | 2021-2022 | |
| Abbvie INC. | $83.57 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $81.86 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $72.76 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.70 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.37 | 2020 | |
| Insulet Corporation | $49.04 | 2019 | |
| Amarin Pharma, INC. | $45.01 | 2019-2021 | |
| Edwards Lifesciences Corporation | $37.50 | 2021-2022 | |
| Allergan, INC. | $31.02 | 2019-2020 | |
| Esperion Therapeutics, INC. | $25.41 | 2020 | |
| Arbor Pharmaceuticals, INC. | $21.41 | 2019 | |
| Ibsa Pharma INC. | $16.70 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.48 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.36 | 2019 | |
| Optinose US, INC. | $14.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.40 | 2022 | |
| Currax Pharmaceuticals LLC | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Judy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.